Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Apollomics Inc. Warrant (APLMW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: APLMW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 122.66M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.03 - 0.03 | Updated Date 06/28/2025 |
52 Weeks Range 0.03 - 0.03 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 20542439 | Price to Sales(TTM) - |
Enterprise Value 20542439 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.12 | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Apollomics Inc. Warrant
Company Overview
History and Background
It's difficult to provide detailed information on the Apollomics Inc. Warrant without knowing its exact stock ticker symbol or other defining information. The details would depend on the specific warrant associated with Apollomics or a SPAC-related entity. A warrant represents the right to purchase shares of a company at a specific price within a specified timeframe.
Core Business Areas
- Biopharmaceutical Development: Likely focused on the research, development, and commercialization of oncology drugs. However, without a specific ticker or warrant definition, it is challenging to confirm and provide comprehensive details.
Leadership and Structure
Information unavailable without a specific ticker symbol.
Top Products and Market Share
Key Offerings
- N/A: Without the specific ticker or warrant definition for Apollomics Inc. Warrant, it is impossible to assess product offerings, market share, or competitors.
Market Dynamics
Industry Overview
The pharmaceutical industry, especially in oncology, is characterized by intense competition, high regulatory hurdles, and significant R&D investments.
Positioning
Without knowing the specific stock ticker, I cannot give specifics on Apollomics Inc. Warrant's position within the industry.
Total Addressable Market (TAM)
The global oncology market is substantial, projected at hundreds of billions of USD. The position is dependent on the warrant details.
Upturn SWOT Analysis
Strengths
- Strong management team (speculative)
- Innovative technology platform (speculative)
- Strategic partnerships (speculative)
Weaknesses
- Dependence on clinical trial outcomes (speculative)
- High cash burn rate (speculative)
- Regulatory hurdles (speculative)
Opportunities
- Expansion into new therapeutic areas (speculative)
- Collaboration with larger pharmaceutical companies (speculative)
- Successful commercialization of lead drug candidate (speculative)
Threats
- Competition from established pharmaceutical companies (speculative)
- Unsuccessful clinical trials (speculative)
- Changes in regulatory landscape (speculative)
Competitors and Market Share
Key Competitors
Competitive Landscape
Dependent on the specifics of the Apollomics Inc. Warrant, I cannot list any Key Competitors.
Growth Trajectory and Initiatives
Historical Growth: Cannot determine historical growth without financial data associated with the specific warrant.
Future Projections: Future projections depend heavily on clinical trial outcomes, regulatory approvals, and market acceptance of the drug, which is specific to the warrant.
Recent Initiatives: No recent initiatives can be specified with limited information.
Summary
Without a specific stock ticker symbol, accurately assessing Apollomics Inc. Warrant's strengths and weaknesses is impossible. The value of the warrant hinges on the future success of the underlying company's drug development programs, market factors, and financial performance. The high-risk, high-reward nature of the biopharmaceutical industry adds a layer of complexity. Investors need thorough research and understand the warrant's terms.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Publicly available information on the pharmaceutical industry
Disclaimers:
The information provided is based on limited information and assumptions due to the lack of a specific ticker symbol for Apollomics Inc. Warrant. This is not financial advice. Do your research and consult with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Apollomics Inc. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-26 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website |
Full time employees 59 | Website | ||
Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.